TD Cowen analyst Boris Peaker reiterated a Buy rating on Moonlake Immunotherapeutics (NASDAQ: MLTX).The analyst commented, "MLTX reviewed SLK's data ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE